Roth Comments on Regeneron (REGN) Following ODYSSEY Update at AHA (SNY)

Roth Capital affirms its Buy rating and $461.00 price target on Regeneron (Nasdaq: REGN) following the presentation of new details regarding six ODYSSEY studies that achieved their endpoints as announced the past July at the American Heart Association (AHA) Scientific Sessions in Chicago, IL. More on that here.

Analyst Joseph Pantginis commented, With ten published ODYSSEY studies achieving their endpoints, REGN and Sanofi (NYSE: SNY) expect to submit U.S. and E.U. regulatory filings for alirocumab by the end of the year. The companies intend on using the previously acquired Priority Review voucher to expedite the review process, which could potentially see the drug running head to head with Amgen's (Nasdaq: AMGN) evolocumab, which has a PDUFA date of August 27, 2015. Regarding Eylea, it was just approved for DME in Japan and is awaiting a regulatory decision for BRVO in Japan and EU.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Regeneron Pharma closed at $413.22 yesterday.

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $1,099 at UBS
• QuantumScape (QS) PT Lowered to $6 at Truist Securities
• Banner Corporation (BANR) PT Lowered to $51 at Piper Sandler